Alector (DB:0Z2) - Stock Price, News & Analysis

0Z2 Stock Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.

About the company

0Z2 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 22.51% per year

Risk Analysis

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Alector, Inc. Competitors

Formycon

XTRA:FYB

€690.5m

Biotest

XTRA:BIO3

€1.4b

MorphoSys

XTRA:MOR

€2.6b

Heidelberg Pharma

XTRA:HPHA

€141.7m

Price History & Performance

Summary of all time highs, changes and price drops for Alector
Historical stock prices
Current Share Price	US$4.98
52 Week High	US$7.95
52 Week Low	US$3.50
Beta	0.78
1 Month Change	-9.45%
3 Month Change	-11.86%
1 Year Change	-14.87%
3 Year Change	-67.24%
5 Year Change	-72.56%
Change since IPO	-66.26%

Recent updates

Shareholder Returns

	0Z2	DE Biotechs	DE Market
7D	0.8%	-3.1%	1.8%
1Y	-14.9%	-22.4%	2.2%

Return vs Industry: 0Z2 exceeded the German Biotechs industry which returned -22.4% over the past year.

Return vs Market: 0Z2 underperformed the German Market which returned 2.2% over the past year.

Price Volatility

Is 0Z2's price volatile compared to industry and market?
0Z2 volatility
0Z2 Average Weekly Movement	9.3%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 0Z2's share price has been volatile over the past 3 months.

Volatility Over Time: 0Z2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2013	244	Arnon Rosenthal	www.alector.com

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease.

Alector, Inc. Fundamentals Summary

How do Alector's earnings and revenue compare to its market cap?
0Z2 fundamental statistics
Market cap	€477.76m
Earnings (TTM)	-€121.84m
Revenue (TTM)	€90.69m

5.2x

P/S Ratio

-3.9x

P/E Ratio

Is 0Z2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0Z2 income statement (TTM)
Revenue	US$97.06m
Cost of Revenue	US$192.12m
Gross Profit	-US$95.05m
Other Expenses	US$35.34m
Earnings	-US$130.39m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.36
Gross Margin	-97.93%
Net Profit Margin	-134.34%
Debt/Equity Ratio	0%

How did 0Z2 perform over the long term?

See historical performance and comparison

0Z2 Stock Overview

Rewards

Risk Analysis

Alector, Inc. Competitors

XTRA:FYB

€690.5m

XTRA:BIO3

€1.4b

XTRA:MOR

€2.6b

XTRA:HPHA

€141.7m

Price History & Performance

Recent News & Updates

Co-Founder recently sold €120k worth of stock

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.62 loss in FY 2022)

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

Recent updates

Co-Founder recently sold €120k worth of stock

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.62 loss in FY 2022)

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Insufficient new directors

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold €122k worth of stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Third quarter 2023 earnings released: US$0.53 loss per share (vs US$0.56 loss in 3Q 2022)

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Second quarter 2023 earnings released: EPS: US$0.016 (vs US$0.12 in 2Q 2022)

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings released: US$0.55 loss per share (vs US$0.54 loss in 1Q 2022)

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold €89k worth of stock

Key Executive recently sold €79k worth of stock

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$1.56 profit in 3Q 2021)

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Second quarter 2022 earnings released: EPS: US$0.12 (vs US$0.69 loss in 2Q 2021)

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.66 loss in 1Q 2021)

Insufficient new directors

Alector, Inc. Announces Appointment of Gary Romano as Chief Medical Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Forecast breakeven date pushed back to 2023

Alector, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: EPS US$1.56 (vs US$0.67 loss in 3Q 2020)

Insufficient new directors

Alector Announces First Participant Dosed in Phase 2 Study Evaluating Al001 in Amyotrophic Lateral Sclerosis (Als)

Forecast to breakeven in 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.58 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.54 loss in 1Q 2020)

Advisor has left the company

Revenue misses expectations

Full year 2020 earnings released: US$2.45 loss per share (vs US$1.71 loss in FY 2019)

New 90-day high: €16.40

Alector, Inc. Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

Alector, Inc. Announces Executive Changes

New 90-day high: €13.70

New 90-day high: €12.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.67 loss per share

New 90-day low: €8.50

New 90-day low: €9.45

New 90-day low - €10.70

First half earnings released